PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 3/28/2024
Go back to PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
October 5, 2021 8:01 AM EDT
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo
Represents most advanced clinical trial of a rationally defined bacterial consortium candidate
BARDA exercises $23.8 million option to support Phase 3 clinical trial of VE303, to initiate in 2022
BOSTON--(BUSINESS... More